News >

Next-Generation Agents Accelerate Advances in ALK+ and ROS1+ NSCLC

Caroline Seymour
Published: Friday, Nov 22, 2019

Nisha A. Mohindra,MD, an assistant professor of medicine in the Hematology/Oncology Division of Northwestern University's Feinberg School of Medicine

Nisha A. Mohindra, MD

With the development of selective TKIs, it’s no longer a question of whether ALK-positive and ROS1-positive non–small cell lung cancer (NSCLC) can be targeted, but rather how to select the optimal therapy among a growing roster of treatments, according to Nisha A. Mohindra, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication